All
Phase 2 Study of VERU-111 in Prostate Cancer Subgroup Completes Patient Enrollment
September 30th 2020VERU Inc. announced it has completed enrollment of 40 men with metastatic prostate cancer who have become resistant to at least one androgen receptor targeting agent for its phase 2 study of VERU-111.
Experimental Treatment Shows Promise for Certain Cases of Advanced NSCLC
September 23rd 2020There is no approved treatment that targets the KRAS p.G12C mutation that drives some cancers like non-small cell lung cancer. But a recent study shows how the experimental drug sotorasib sparked responses in some patients with advanced non-small cell lung cancer that harbored the mutation.